EU/3/16/1732

About

On 29 August 2016, orphan designation (EU/3/16/1732) was granted by the European Commission to Biogen Idec Limited, United Kingdom, for synthetic ribonucleic acid oligonucleotide directed against superoxide dismutase 1 messenger ribonucleic acid (also known as BIIB067) for the treatment of amyotrophic lateral sclerosis.

The sponsorship was transferred to Biogen Netherlands B.V., Netherlands, in May 2019.

 

Key facts

Active substance
Synthetic ribonucleic acid oligonucleotide directed against superoxide dismutase 1 messenger ribonucleic acid
Disease / condition
Treatment of amyotrophic lateral sclerosis
Date of first decision
29/08/2016
Outcome
Positive
EU designation number
EU/3/16/1732

Review of designation


The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Biogen Netherlands B.V.
Prins Mauritslaan 13-19
Badhoevedorp
Noord-Holland
1171 LP
Netherlands
Tel. + 31 20 542 2140
E-mail: ukreceptiondesk@biogen.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating